Latest Kidney Cancer News
Kidney Cancer News elsewhere on the Web
In an interview, Jaime Merchan, MD, explained the background and data from a biomarker analysis of the CLEAR trial in advanced renal cell carcinoma.
Background Circulating tumor cells (CTCs) are pivotal in tumor metastasis across cancers, yet their specific role in renal cancer remains unclear. Methods This study investigated C–C motif chemokine ligand 5 (CCL5)'s tumorigenic impact on renal cancer cells and CTCs using bioinformatics, in ...
Cabometyx® is now available on the Pharmaceutical Benefits Scheme (PBS) for the treatment of Stage IV non-clear cell renal cell carcinoma (nccRCC).1,2 Previously patients with Stage IV nccRCC had no PBS-reimbursed treatment option.2 NccRCC is a diverse group of tumours with distinct unique ...
Bradley McGregor, MD, discusses how abemaciclib monotherapy did not elicit clinically meaningful activity in heavily pretreated metastatic clear cell RCC.
Nazli Dizman, MD, discusses next steps planned for research with CBM588 in patients with renal cell carcinoma in the first line.
Numerous studies have shown that the Krüppel-like factors (KLFs) family of transcription factors regulate various eukaryotic physiological processes including the proliferation, differentiation, senescence, death, and carcinogenesis of animal cells. In addition, they are involved in the ...
Compared to sunitinib, nivolumab plus ipilimumab showed increased overall survival and durable response benefits in patients with advanced renal cell carcinoma.
SHC1 plays a crucial regulatory role in various tumors, but its significance in predicting prognosis and immune response in clear cell renal cell carcinoma (ccRCC) is yet to be determined. In this study, we conducted a bioinformatics analysis of SHC1 expression, prognosis, and immunological ...
SHC1 plays a crucial regulatory role in various tumors, but its significance in predicting prognosis and immune response in clear cell renal cell carcinoma (ccRCC) is yet to be determined. In this study, we conducted a bioinformatics analysis of SHC1 expression, prognosis, and immunological ...
Viktor Grünwald, MD, PhD, discusses differences in tumor burden between patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab vs sunitinib.
No results found.
Articles from Kidney Cancer UK
No results found.
No results found.